New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 23, 2014
15:04 EDTNVSNovartis chairman says continued R&D investment necessary, WSJ says
According to the chairman of Novartis, Joerg Reinhardt, the drug company needs to continue its investment on research and development to develop new drugs that national health-care systems are willing pay for, says the Wall Street Journal. Reference Link
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
June 18, 2015
17:05 EDTNVSNovartis announces U.S. launch of Glatopa
Sandoz, a Novartis (NVS) company, announced the U.S. launch of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy.
11:54 EDTNVSAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
06:57 EDTNVSMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
June 16, 2015
10:29 EDTNVSGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
05:45 EDTNVSNovartis to host two day investor event
Subscribe for More Information
05:40 EDTNVSNovartis division Alcon receives CE Mark for AcrySof IQ PanOptix trifocal IOL
Alcon, a division of Novartis, has received European CE Mark for its AcrySof IQ PanOptix trifocal intraocular lens, or IOL, for patients undergoing cataract surgery who elect to address their near, intermediate, and distance vision needs with a single lens. The AcrySof IQ PanOptix trifocal IOL is an important addition to Alcon's broad portfolio of intraocular lenses for cataract patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use